SVA

Sinovac Biotech Lt

Healthcare Biotechnology NASDAQ

About the company

Sinovac Biotech Ltd is a leading biopharmaceutical company based in China, known for its expertise in the research, development, manufacturing, and commercialization of vaccines for infectious diseases. With a strong focus on public health, the company has successfully developed and marketed vaccines against various diseases, including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. As one of the few Chinese vaccine manufacturers with a global presence, Sinovac has been at the forefront of disease control and prevention efforts, collaborating closely with the Chinese government at national, state, and local levels. The company's dedication to quality and safety has earned it the trust of healthcare professionals, regulators, and patients alike. Sinovac is committed to addressing public health challenges not only in China but also in international markets. In China, Sinovac has established a strong presence, making its vaccines available to a large population. Through strategic partnerships, the company has ensured widespread distribution and accessibility of its vaccines across the country. Sinovac's vaccines have played a crucial role in reducing the burden of infectious diseases in China and protecting millions of lives. While Sinovac's primary market is in China, the company is also focused on exploring growth opportunities in international markets. With its track record of success, Sinovac's vaccines have gained recognition and acceptance in various countries. In recent years, the company has expanded its reach and entered into partnerships to bring its vaccines to a global audience. In addition to its product portfolio, Sinovac provides comprehensive services for disease control and prevention. The company collaborates with the Chinese government to develop and implement vaccination programs, guiding public health policies and supporting disease surveillance efforts. Sinovac's expertise and experience in this field have made it a trusted partner in the fight against infectious diseases. Sinovac's commitment to research and development is a cornerstone of its success. The company invests heavily in research to continuously improve existing vaccines and develop new ones. By leveraging its scientific expertise and innovative technologies, Sinovac aims to address emerging infectious diseases and contribute to global health security. The future looks promising for Sinovac Biotech Ltd. With an expanding product portfolio, a strong market presence in China, and growing international recognition, the company is well-positioned to continue its mission of protecting public health. By advancing vaccine development and collaborating with governments and healthcare institutions worldwide, Sinovac strives to make a positive and lasting impact on global public health.

Website: http://www.sinovacbio.com

Data updated: June 2, 2026

Sector comparison

We compare this company with the typical (middle) company in the same industry to show how it looks against similar businesses. This is information, not a recommendation.

Healthcare · 1345 peers in sector

Metric SVA Sector median Vs. industry
P/E 6.66 20.13 ↓ Below average
EPS 0.97 USD -1.14 USD ↑ Above average
Dividend yield 8.50% 0.00% ↑ Above average
Profit margin 21.61% 0.00% ↑ Above average
ROE 25.16% -58.89% ↑ Above average

Higher and lower here are only a comparison with the typical company in the industry — a higher or lower value on its own does not mean better or worse.

Financial statements & historical data

Income statements, balance sheets, cash flow, earnings and dividend history are available for registered users

Sign up for free

AI Summary

AI-generated company analysis is available for registered users.

Sign up for free

Where does this data come from?

Frequently Asked Questions

What is Sinovac Biotech Lt?
Sinovac Biotech Ltd is a leading biopharmaceutical company based in China, known for its expertise in the research, development, manufacturing, and commercialization of vaccines for infectious diseases. With a strong focus on public health, the company has successfully developed and marketed vaccines against various diseases, including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. As one of the few Chinese vaccine manufacturers with a global presence, Sinovac has been at the forefront of disease control and prevention efforts, collaborating closely with the Chinese government at national, state, and local levels. The company's dedication to quality and safety has earned it the trust of healthcare professionals, regulators, and patients alike. Sinovac is committed to addressing public health challenges not only in China but also in international markets. In China, Sinovac has established a strong presence, making its vaccines available to a large population. Through strategic partnerships, the company has ensured widespread distribution and accessibility of its vaccines across the country. Sinovac's vaccines have played a crucial role in reducing the burden of infectious diseases in China and protecting millions of lives. While Sinovac's primary market is in China, the company is also focused on exploring growth opportunities in international markets. With its track record of success, Sinovac's vaccines have gained recognition and acceptance in various countries. In recent years, the company has expanded its reach and entered into partnerships to bring its vaccines to a global audience. In addition to its product portfolio, Sinovac provides comprehensive services for disease control and prevention. The company collaborates with the Chinese government to develop and implement vaccination programs, guiding public health policies and supporting disease surveillance efforts. Sinovac's expertise and experience in this field have made it a trusted partner in the fight against infectious diseases. Sinovac's commitment to research and development is a cornerstone of its success. The company invests heavily in research to continuously improve existing vaccines and develop new ones. By leveraging its scientific expertise and innovative technologies, Sinovac aims to address emerging infectious diseases and contribute to global health security. The future looks promising for Sinovac Biotech Ltd. With an expanding product portfolio, a strong market presence in China, and growing international recognition, the company is well-positioned to continue its mission of protecting public health. By advancing vaccine development and collaborating with governments and healthcare institutions worldwide, Sinovac strives to make a positive and lasting impact on global public health.
Are Sinovac Biotech Lt shares expensive?
The price-to-earnings (P/E) ratio of Sinovac Biotech Lt is 6.66 — the share price is 6.66 times the annual profit per share. That is lower than the typical company in the same industry (industry median: 20.13). This is information, not a recommendation. (as of 2026-06-02)
How big is Sinovac Biotech Lt?
The market capitalization of Sinovac Biotech Lt — the combined value of all its shares — is 642.4 M USD. The higher the market cap, the larger the company. (as of 2026-06-02)
Does Sinovac Biotech Lt pay dividends?
The dividend yield of Sinovac Biotech Lt is 8.50% — it shows the annual dividend relative to the share price. This is information, not a recommendation. (as of 2026-06-02)
What sector does Sinovac Biotech Lt belong to?
Sinovac Biotech Lt operates in the Healthcare sector, industry: Biotechnology.

What do you gain?

With Ecrumen you gain full control over your investments and assets!

All your assets
Stock market investments, real estate, bonds. Be aware of what you have in your portfolio!
AI at the service of your investments
Analyze and optimize your investments using the latest technologies. Sentiments, analyses, tips, reports. Always with up-to-date data!
A community eager to help
Find a place with people similar to you. Share your opinions, see how others manage their investments. Get help with the problems that bother you!
What do you gain?

Want to stay up to date?

Subscribe to our newsletter to stay up to date with Ecrumena news and market information. No spam, unsubscribe in one click.

For more information, please refer to our terms of use.

0/120